**Question:** Orally effective iron chelating agent:

A. Deferoxamine
B. Deferasirox
C. Deferiprone
D. Deferoxamine + Deferasirox

**Core Concept:** Iron chelation therapy is used in the treatment of iron overload conditions such as hemochromatosis, thalassemia, and hemosiderosis. Chelating agents bind to excess iron ions and facilitate their excretion from the body, reducing tissue iron accumulation.

**Why the Correct Answer is Right:** Deferasirox (Option B) is a potent orally administered iron chelating agent that selectively binds to and removes iron from the body. It is particularly effective for chronic iron overload conditions, such as transfusion-dependent anemias (e.g., thalassemia, polycythemia), and is administered orally, making it convenient for patients.

**Why Each Wrong Option is Incorrect:**

A. Deferoxamine (Option A) is an intravenous iron chelating agent used for acute iron poisoning and transfusion reactions. It is not suitable for long-term oral administration due to its parenteral nature and potential side effects.

Both C (Deferiprone) and D (Deferoxamine + Deferasirox) are incorrect because:

C. Deferiprone (Option C) is an oral iron chelating agent but is associated with significant side effects, such as agranulocytosis and gastrointestinal issues. It has limited indications and is not the first-choice agent for oral iron chelation therapy.

D. Combining Deferoxamine (Option D) and Deferasirox (Option D) does not increase the efficacy of iron chelation therapy, as they target different iron-binding sites and have distinct pharmacokinetic properties.

**Clinical Pearl:** Deferasirox (Option B) stands out as the preferred orally administered iron chelating agent due to its ease of administration, oral route, and proven efficacy in chronic iron overload conditions.

**Correct Answer:** Deferasirox (Option B) is an effective, oral iron chelating agent for the management of chronic iron overload conditions. Its oral administration makes it more patient-friendly compared to Deferoxamine, which requires intravenous administration. Deferasirox has been demonstrated to effectively reduce body iron levels in patients with chronic kidney disease on hemodialysis and other indications.